SCHEMBL13600201

SCHEMBL13600201

CN(C)C(=O)c1cc(-c2cnc3c(c2)c(Cc2cccc(Cl)c2)nn3C)ccc1NC(=O)N1CCOCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
PRMT6 Q96LA8 2/20 0.38
AOC3 Q16853 2/20 0.38
NTRK1 P04629 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CTSS P25774 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CNR1 P21554 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12344668 0.89 KDM4E (0.36) ALDH1A1KDM4EHPGDPRMT6AOC3
SCHEMBL12344670 0.87 NTRK1 (0.40) ALDH1A1KDM4EHPGDPRMT6AOC3
SCHEMBL3488948 0.87 KDM4E (0.35) ALDH1A1KDM4EHPGDPRMT6AOC3
SCHEMBL12344667 0.79 CLK2 (0.41) PRMT6AOC3NTRK1DYRK1A
SCHEMBL12344640 0.74 HDAC3 (0.39) PRMT6NTRK1GSK3BDYRK1ACYP3A4
SCHEMBL13600199 0.73 MAPK1 (0.41) GSK3BCYP3A4MAPK1
SCHEMBL13342408 0.71 HSD17B10 (0.37) ALDH1A1KDM4EHPGDPRMT6GSK3B
SCHEMBL13342174 0.69 MAP4K1 (0.66) NTRK1
SCHEMBL12343709 0.68 MAP4K1 (0.49) ALDH1A1TSHRNPC1RAB9ACYP3A4
SCHEMBL3489336 0.67 MAP4K1 (0.43) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626021-B2 Fused ring heterocycle kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287711-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, TTK, MAP3K19 ALDH1A1 4383/4885KDM4E 832/4885HPGD 2710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.